Regular ArticleRegional Specificity of Brain Atrophy in Huntington's Disease☆
References (55)
- et al.
Intranuclear neuronal inclusions in Huntington's disease and dentorubral and pallidoluysian atrophy: Correlation between the density of inclusions and IT15 CAG triplet repeat length
Neurobiol. Dis.
(1998) - et al.
Ubiquitin-reactive neurites in cerebral cortex of subjects with Huntington's chorea: A pathological correlate of dementia
Neurosci. Lett.
(1993) - et al.
Topography of brain atrophy during normal aging and Alzheimer's disease
Neurobiol. Aging
(1996) - et al.
Cerebral structure on MRI, Part II: Specific changes in Alzheimer's and Huntington's diseases
Biol. Psychiatry
(1991) - et al.
Morphometric studies of the neuropathological changes in choreatic diseases
J. Neurol. Sci.
(1976) - et al.
Clinical presentation and patterns of cerebral atrophy related to the length of trinucleotide repeat expansion in patients with adult onset Huntington's disease
Neurosci. Lett.
(1997) Selective neurodegeneration in Huntington's disease
Ann. Neurol.
(1995)- et al.
Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease
Brain
(1996) - et al.
[11
Ann. Neurol.
(1998) - et al.
Frontal lobe volume in patients with Huntington's disease
Neurology
(1998)
Basal ganglia volume and proximity to onset in presymptomatic Huntington disease
Arch. Neurol.
Longitudinal change in basal ganglia volume in patients with Huntington's disease
Neurology
Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes
Brain
Clinical-pathological correlation in Huntington's disease: A neuropsychological and computed tomography study
Neurology
Positron emission tomographic scan investigations of Huntington's disease: Cerebral metabolic correlates of cognitive function
Ann. Neurol.
Allocortical involvement in Huntington's disease
Neuropathol. Appl. Neurobiol.
Degeneration of pyramidal projection neurons in Huntington's disease cortex
Ann. Neurol.
Morphometric demonstration of atrophic changes in the cerebral cortex, white matter and neostriatum in Huntington's disease
J. Neuropathol. Exp. Neurol.
Aggregation of Huntington in neuronal intranuclear inclusions and dystrophic neurites in brain
Science
Regional brain atrophy in idiopathic Parkinson's disease and diffuse Lewy body disease
Dementia
Parvalbumin-immunoreactive neurons in the cerebral cortex and striatum in Huntington's disease
Neurodegeneration
Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease
Ann. Neurol.
Differential distribution of normal and mutated forms of Huntington in the human brain
Ann. Neurol.
Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers
J. Neurol. Neurosurg. Psychiatry
Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: A proton magnetic resonance spectroscopy study
J. Neurol. Neurosurg. Psychiatry
Single photon emission computed tomographic blood flow and magnetic resonance volume imaging of basal ganglia in Huntington's disease
Arch. Neurol.
The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease
Neurology
Cited by (200)
N-terminal mutant huntingtin deposition correlates with CAG repeat length and symptom onset, but not neuronal loss in Huntington's disease
2022, Neurobiology of DiseaseCitation Excerpt :The potential applications of this finding were further highlighted when a negative correlation was found between mutant Htt in the cerebrospinal fluid of late-stage HD patients and symptom onset, therefore Htt detection may be used as a diagnostic tool to predict the clinical onset of HD (Southwell et al., 2015). As previously reported and confirmed within our HD cohort (Supplementary Fig. 1) there is a well-established negative relationship between CAG repeat length and the onset of symptoms, and the results from this study suggest a critical role for Htt aggregates in the underlying pathological mechanism driving HD clinical presentation (Andrew et al., 1993; Duyao et al., 1993; Halliday et al., 1998). There was no significant relationship between the number of MAB5374+, MW1+, or EPR5526+ Htt aggregates and the density of SMI-32+ pyramidal cells in the MTG TMA, which suggests the number of aggregates does not correlate with pyramidal cell loss.
Measuring movement in health and disease
2022, Brain Research BulletinThe microbiota-gut-brain axis in Huntington's disease
2022, International Review of NeurobiologyDynamics of Cortical Degeneration Over a Decade in Huntington's Disease
2021, Biological PsychiatryGene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease
2024, Frontiers in Neuroscience
- ☆
A. B. JosephR. R. Young